Acta Virol. 2020 Sep 28. doi: 10.4149/av_2020_402. Online ahead of print.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undoubtedly created an emerging disease of topmost public health priority spilling throughout the globe. The diagnosis currently relies on a multiplex of criteria including the epidemiology, clinical manifestations and in vitro diagnostics. Presently, the real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) is considered as the most reliable assay for the detection of SARS-CoV-2 and is being supplemented by other auxiliary tests, including serology and radiology. Many of these molecular and immunological tests have been validated by the Indian Council of Medical Research (ICMR) and the Food and Drug Administration (FDA) and commercial kits have been introduced in the field. But, considering the sensitivity and specificity based shortcomings and the lacunae in monitoring the spread of the virus, there is an immense need to develop integrated smart devices based on novel, safe, rapid and accurate diagnostic techniques and implement them on a large scale to curb this outbreak in the country and the world as a whole. Keywords: clinical manifestations; COVID-19; diagnosis; PCR; SARS-COV-2; serology.
PMID:32985200 | DOI:10.4149/av_2020_402